Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 5/20 | 0.54 |
| ▸ | PDE1A | P54750 | 5/20 | 0.54 |
| ▸ | PDE1B | Q01064 | 5/20 | 0.54 |
| ▸ | PDE1C | Q14123 | 5/20 | 0.54 |
| ▸ | PDE5A | O76074 | 2/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | PNP | P00491 | 1/20 | 0.36 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6374085 | 0.88 | PDE9A (0.56) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6365996 | 0.86 | PDE1A (0.57) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6366324 | 0.86 | PDE9A (0.48) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6366835 | 0.86 | PDE9A (0.74) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6281743 | 0.86 | PDE9A (0.57) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL3492432 | 0.85 | PDE9A (0.73) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6367359 | 0.82 | PDE9A (0.50) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6367623 | 0.82 | PDE9A (0.48) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6365536 | 0.81 | PDE9A (0.50) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL5065505 | 0.81 | PDE9A (0.52) | PDE9APDE1APDE1BPDE1CPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1440073-A1 | PDE9 INHIBITORS FOR TREATING CARDIOVASCULAR DISORDERS | Pfizer Limited (GB) | 2004-07-28 | — | — | EP | claimed |
| US-20030195205-A1 | PDE9 inhibitors for treating cardiovascular disorders | PFIZER INC. | 2003-10-16 | — | — | US | claimed |
| WO-2003037899-A1 | PDE9 INHIBITORS FOR TREATING CARDIOVASCULAR DISORDERS | PFIZER LIMITED (GB) | 2003-05-08 | — | — | WO | claimed |
| US-20100113484-A1 | TREATING AGENT OF UROPATHY | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2123301-A1 | THERAPEUTIC AGENT FOR URINARY TRACT DISEASE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-6967204-B2 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC (US) | 2005-11-22 | — | — | US | disclosed |
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC | 2005-03-31 | — | — | US | disclosed |
| EP-1440073-A1 | PDE9 INHIBITORS FOR TREATING CARDIOVASCULAR DISORDERS | Pfizer Limited (GB) | 2004-07-28 | — | — | EP | disclosed |
| US-20030195205-A1 | PDE9 inhibitors for treating cardiovascular disorders | PFIZER INC. | 2003-10-16 | — | — | US | disclosed |
| WO-2003037899-A1 | PDE9 INHIBITORS FOR TREATING CARDIOVASCULAR DISORDERS | PFIZER LIMITED (GB) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113484-A1 | TREATING AGENT OF UROPATHY | BPHL, PDE12, UROD | PDE9A 6/4885PDE1A 44/4885PDE1B 41/4885 |
| US-20030195205-A1 | PDE9 inhibitors for treating cardiovascular disorders | PDE9A, PDE2A, PDE3A | PDE9A 1/4885PDE1A 62/4885PDE1B 50/4885 |
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | GPR119, PDE2A, PDE9A | PDE9A 3/4885PDE1A 46/4885PDE1B 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.